Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laronidase - BioMarin/Sanofi

Drug Profile

Laronidase - BioMarin/Sanofi

Alternative Names: Aldurazyme; Alpha-L-iduronidase; BM 101; JC 0498; rh alpha-L-iduronidase

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMarin Pharmaceutical; Genzyme Corporation
  • Developer BioMarin Pharmaceutical; Sanofi; University of California at Los Angeles
  • Class Glycoside hydrolases; Recombinant fusion proteins
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis I

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mucopolysaccharidosis-I(In children) in USA (Intrathecal, Injection)
  • 08 Aug 2017 Launched for Mucopolysaccharidosis I in Russia and Hong Kong (IV) before August 2017
  • 15 Feb 2017 Interim pharmacodynamics data from a trial in mucopolysaccharidosis type I (Hurler syndrome) released by Sanofi Genzyme
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top